Mechanism of Action.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide (a NAD+ precursor) to form 1-methylnicotinamide (1-MNA). NNMT is overexpressed in obesity and metabolic dysfunction. By inhibiting NNMT, 5-Amino-1MQ increases the intracellular pool of nicotinamide available for NAD+ synthesis, effectively boosting cellular NAD+ levels. Higher NAD+ activates sirtuin enzymes (SIRT1-7) and AMPK, promoting fatty acid oxidation, mitochondrial biogenesis, and energy expenditure. Additionally, NNMT inhibition reduces the availability of SAM (S-adenosyl methionine), the universal methyl donor, which modulates epigenetic methylation patterns associated with adipogenesis and lipid storage. The net effect is increased cellular energy expenditure and reduced fat accumulation.
Research Summary.
Research from the University of Texas demonstrated that NNMT inhibition with 5-Amino-1MQ reduced body weight and adipocyte size in diet-induced obese mice without affecting food intake, suggesting increased energy expenditure rather than appetite suppression. The compound reduced white adipose tissue mass, improved glucose tolerance, and decreased cholesterol levels. Cell culture studies showed that NNMT inhibition reduced adipogenesis (fat cell formation) and increased basal metabolic rate in treated adipocytes. The mechanism is notable because it works through a different pathway than GLP-1 agonists, potentially offering complementary effects. However, human clinical data is not available, and the compound is still in early-stage research.
Side Effects & Safety.
Safety data for 5-Amino-1MQ is limited to preclinical studies. In mouse studies, no significant adverse effects were observed at effective doses. Theoretical concerns include effects on SAM-dependent methylation processes (since NNMT inhibition alters methyl donor availability), potential impacts on nicotinamide metabolism beyond the intended pathway, and unknown long-term effects of chronic NNMT inhibition on epigenetic regulation. As a small molecule rather than a peptide, it may have different pharmacokinetic and toxicological considerations. Comprehensive safety assessment awaits human clinical trials.
Legal Status & Access.
5-Amino-1MQ is classified as a research compound. It is not FDA-approved for any clinical indication. Available from some research suppliers. It is technically a small molecule rather than a peptide but is commonly offered by peptide research vendors.